InvestorsHub Logo
Followers 58
Posts 10124
Boards Moderated 1
Alias Born 09/21/2016

Re: georgejjl post# 437413

Saturday, 10/28/2023 9:51:43 AM

Saturday, October 28, 2023 9:51:43 AM

Post# of 461369
georgejji

"...We also look forward to presenting in an upcoming major publication the complete dataset of the Phase 2b/3 Alzheimer’s disease trial of ANAVEX®2-73 (blarcamesine), a potential next-generation precision medicine convenient once daily oral Alzheimer’s disease treatment,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.

"We are also on track within our neurodevelopmental precision medicine Rett syndrome program to release top-line data of ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the current quarter of 2023.”

https://www.anavex.com/post/anavex-life-sciences-reports-new-publication-in-scientific-journal-demonstrating-the-potential-of



I view this quote from Dr.M. as the most direct, impactful and urgently needed statement I have seen from him in 10+ years.
I would urge Dr.M. and the exec. team to quickly and effectively act to make this happen. NOW.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News